Y. Sahakyan, “Cost-utility of minimally invasive therapies vs. pharmacotherapy as initial therapy for benign prostatic hyperplasia: A Canadian healthcare payer perspective”, CUAJ, vol. 17, no. 4, pp. 103–10, Dec. 2022.